📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! Tell us what works, what doesn't, and how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community. Please send your feedback to gateway@ukri.org by 11 August 2025.

Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. (2021)

First Author: Kennedy NA

Attributed to: Regulatory T cell therapy for IBD funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1136/gutjnl-2021-324388

PubMed Identifier: 33753421

Publication URI: http://europepmc.org/abstract/MED/33753421

Type: Journal Article/Review

Volume: 70

Parent Publication: Gut

Issue: 5

ISSN: 0017-5749